Dilaterol 0.025 mg/ml Sirup Repubblika Ċeka - Ċek - USKVBL (Ústav Pro Státní Kontrolu Veterinárních Biopreparátů A Léčiv)

dilaterol 0.025 mg/ml sirup

le vet beheer, b.v. - clenbuterol - sirup - selektivní beta-2-adrenoreceptor agonistů - koně

Atectura Breezhaler Unjoni Ewropea - Ċek - EMA (European Medicines Agency)

atectura breezhaler

novartis europharm limited  - indacaterol acetate, mometasone furoate - astma - léky na obstrukční onemocnění dýchacích cest, - atectura breezhaler is indicated as a maintenance treatment of asthma in adults and adolescents 12 years of age and older not adequately controlled with inhaled corticosteroids and inhaled short acting beta2-agonists.

Enerzair Breezhaler Unjoni Ewropea - Ċek - EMA (European Medicines Agency)

enerzair breezhaler

novartis europharm limited - indacaterol, glycopyrronium bromide, mometasone - astma - léky na obstrukční onemocnění dýchacích cest, - enerzair breezhaler is indicated as a maintenance treatment of asthma in adult patients not adequately controlled with a maintenance combination of a long acting beta2 agonist and a high dose of an inhaled corticosteroid who experienced one or more asthma exacerbations in the previous year.

Sitagliptin / Metformin hydrochloride Mylan Unjoni Ewropea - Ċek - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride mylan

mylan ireland limited - sitagliptin hydrochloride monohydrate, metformin hydrochloride - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:sitagliptin/metformin hydrochloride mylan is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. sitagliptin/metformin hydrochloride mylan is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. sitagliptin/metformin hydrochloride mylan is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparg) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparg agonist. sitagliptin/metformin hydrochloride mylan is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

Vydura Unjoni Ewropea - Ċek - EMA (European Medicines Agency)

vydura

pfizer europe ma eeig  - rimegepant - poruchy migrény - antimigraine preparations, calcitonin gene-related peptide (cgrp) antagonists - vydura is indicated for theacute treatment of migraine with or without aura in adults;preventative treatment of episodic migraine in adults who have at least 4 migraine attacks per month.

Sitagliptin / Metformin hydrochloride Accord Unjoni Ewropea - Ċek - EMA (European Medicines Agency)

sitagliptin / metformin hydrochloride accord

accord healthcare s.l.u. - metformin hydrochloride, sitagliptin hydrochloride monohydrate - diabetes mellitus, typ 2 - léky užívané při diabetu - for adult patients with type 2 diabetes mellitus:it is indicated as an adjunct to diet and exercise to improve glycaemic control in patients inadequately controlled on their maximal tolerated dose of metformin alone or those already being treated with the combination of sitagliptin and metformin. it is indicated in combination with a sulphonylurea (i. trojkombinační léčbě) jako doplněk k dietním opatřením a cvičení u pacientů nedostatečně maximální tolerované dávky metforminu a sulfonylmočoviny. it is indicated as triple combination therapy with a peroxisome proliferator-activated receptor gamma (pparγ) agonist (i. , a thiazolidinedione) as an adjunct to diet and exercise in patients inadequately controlled on their maximal tolerated dose of metformin and a pparγ agonist. it is also indicated as add-on to insulin (i. , triple combination therapy) as an adjunct to diet and exercise to improve glycaemic control in patients when stable dose of insulin and metformin alone do not provide adequate glycaemic control.

AMOROLFIN BELUPO 50MG/ML Léčivý lak na nehty Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

amorolfin belupo 50mg/ml léčivý lak na nehty

belupo, s.r.o., bratislava array - 12741 amorolfin-hydrochlorid - léčivý lak na nehty - 50mg/ml - amorolfin

EXOROLAK 50MG/ML Léčivý lak na nehty Repubblika Ċeka - Ċek - SUKL (Státní ústav pro kontrolu léčiv)

exorolak 50mg/ml léčivý lak na nehty

sandoz s.r.o., praha array - 12741 amorolfin-hydrochlorid - léčivý lak na nehty - 50mg/ml - amorolfin